MongoDB Vs Splunk: Which Data Analytics Stock is a Better Bet?

Are you confused about which data analytics stock to buy? Here is a comparison for your understanding

The data industry may be one of the most diverse and complex industries out there, making it hard to clump together all the sectors falling under it. Looking at how fundamental data analytics is to contemporary and future technology, it only makes sense for growth-seeking investors to try and get a slice of the data analytics action. In this article, we will compare MongoDB and Splunk to find which is the better data analytics stock to buy.

MongoDB provides an open-source database platform for businesses, with a subscription-based software-as-a-service business model. It reported fourth-quarter results in early March that came in well above analyst estimates. Currently, the MongoDB data analytics stock is US$377.87, a 7.16% decline from the previous close. Splunk provides intelligence software designed to help organizations search, correlate, analyze, monitor, and report on data in real-time. The software is geared to analyze vast amounts of historical information. They specialize in machine data applications. Currently, the Splunk data analytics stock is US$125.86, a 5.52% decline from the previous close.

MongoDB is one of the top stocks to consider while buying data analytics stocks. MDB operates a leading, modern, general-purpose database platform. Its database market is one of the largest in the software industry. Currently, it has over 24,800 customers in over 100 countries.

Splunk develops and markets software solutions that enable organizations to gain real-time operational intelligence globally. Its software helps capture, index, and correlate real-time data in a searchable repository, which can help generate graphs, reports, alerts, dashboards, and visualizations. Even though SPLK is one of the well-known names in the growing data analytics industry, it continues to face increasing competition from top players in the space. In addition, analysts expect its EPS to remain negative in the coming quarters. So, we think it could be wise to avoid the stock now.